MaxCyte, Inc. (LON:MXCT) is to continue its collaboration with one of the world’s leading infectious disease institutes after it signed a cooperative research and development agreement with the US National Institute of Allergy and Infectious Diseases (NIAD).
The two will work together to explore the development of new therapies for X-linked chronic granulomatous disease (CGD) using MaxCyte’s Flow Electroporation gene-correction platform.
“We are delighted to continue our collaboration with NIAID which is leveraging MaxCyte's expertise in developing a new generation of genome editing therapy for CGD patients,” said President and chief executive Doug Doerfler.
“We believe that this work will validate the use of our platform for developing gene-editing therapies via rapid, cost-effective manufacturing.”
Chronic granulomatous disease
CGD is an inherited genetic disorder that impairs the function of the immune system and leads to ongoing and often severe bacterial infections.
It affects around one in 250,000 people across the globe and is currently only treatable through high-risk treatments such as bone marrow transplants.
Shares edged 2% higher in morning trade to 257.5p.